

COMMUNICATION OF PRIVILEGED INFORMATION

ATRY'S HEALTH, S.A.

13 June 2022

Pursuant to article 226 of the consolidated text of the Spanish Securities Market Act (*Ley del Mercado de Valores*) approved by means of the Royal Legislative Decree 4/2015, 23 October, and to other concordant provisions, ATRYS HEALTH, S.A. ("**ATRY'S**" or the "**Company**") communicates:

That on 7 June, the Company has executed a share purchase agreement to acquire 100% of the share capital of Significant Impact Systems, S.L., which in turn owns 100% of the share capital of Bienzobas Salud, S.L.U. ("**Bienzobas**").

Bienzobas is one of the leading companies in Spain in the provision and management of Medical Oncology services, with a growing presence in Mexico and Portugal, and is responsible for the oncology treatment of a reference population of two million policyholders.

Bienzobas has been collaborating for more than 20 years with hospital groups and health insurance companies in the management of oncology patients and it has more than 70 medical oncologists and oncohematologists working in 40 hospitals of several healthcare groups.

The purchase price amounts to EUR 76.3 million (of which approximately EUR 72.1 million will be paid in cash and EUR 4.27 million will be paid in kind through the delivery of ATRYS' shares). In addition, a contingent earn-out of approximately EUR 18.1 million has been agreed, subject to the level of EBITDA that Bienzobas will achieve in tax year 2022.

Bienzobas recorded at year-end 2021: (i) revenues of EUR 30.62 million; (ii) EBITDA of EUR 8.80 million; and (iii) a positive net income of EUR 1.75 million. As of 31 May 2022, the Company's net debt was EUR 20.2 million.

Bienzobas has developed its own technological platform, based on the use of cloud systems that is interoperable with clinical history systems and it aims to optimizing healthcare management. The new technologies used, such as Big Data and Artificial Intelligence, enable process efficiency and advanced data analytics, managing knowledge and supporting healthcare professionals in decision-making.

With this acquisition, ATRYS: (i) incorporates talent, knowledge and experience in the medical oncology healthcare field; (ii) reinforces its positioning at the diagnostic and clinical level, increasing its capacity to offer global and innovative solutions to health insured groups; and (iii) consolidates the Oncology 360 model in all areas related to the prevention, diagnosis and treatment of cancer, through its technological platform.

In addition, the acquisition implies ATRYS' entry into Mexico, as last January Bienzobas acquired 80% of the Mexican company Gefarma, S.A.P.I. de C.V., which provides medical oncology and cancer treatment services in Mexico City and whose turnover in tax year 2021 amounted to 1.26 million euros.

ATRY'S' management estimates that: (i) the transaction creates shareholder value from the beginning by increasing pro forma adjusted EBITDA per share in 2021 which goes from EUR 0.58 to EUR 0.61 per share (+4.6%) and up to EUR 0.65 per share post achievement of synergies in 2023 (+11.4%); (ii) the transaction will reduce the current Net Financial Debt / pro forma adjusted EBITDA ratio in 2022 from 3.72x to 3.00x significantly improving the Group's solvency profile and its positioning for future acquisitions; (iii) Bienzobas will generate in 2022 approximately EUR 41 million of consolidated revenue and EUR 9 million of adjusted EBITDA; and (iv) the integration of



Bienzobas will allow to meet the M&A growth guidance (approximately EUR 35 million of revenue and EUR 9 million of EBITDA) and with the overall Group guidance (EUR 220 million of pro forma revenue and EUR 50 million of pro forma adjusted EBITDA).

Closing of the transaction is expected to take place before the end of June 2022.

From Atrys' side Pinsent Masons España, S.L.P. has acted as legal counsel and Mediobanca – Banca di Credito Finanziario S.p.A. as financial advisor. Ernst & Young Abogados, S.L.P. has acted as legal counsel to the sellers. In addition, Atrys has engaged PwC to carry out the due diligence.

The acquisition will be financed by ATRYS with a capital increase through an accelerated bookbuild offering, as released to the market in a separate Privileged Information communication today.

Madrid, 13 June 2022

Ms. Isabel Lozano Fernández

Chief Executive Officer